<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04301414</url>
  </required_header>
  <id_info>
    <org_study_id>AAAS3560</org_study_id>
    <nct_id>NCT04301414</nct_id>
  </id_info>
  <brief_title>Non-fucosylated Anti-CTLA-4 (BMS-986218) + Degarelix Acetate vs. Degarelix Acetate Alone in Men With High-risk Localized Prostate Cancer</brief_title>
  <acronym>Neo-Red-P</acronym>
  <official_title>A Pilot Study of Neoadjuvant Non-fucosylated Anti-CTLA-4 (BMS-986218) + Degarelix Acetate vs. Degarelix Acetate Alone in Men With High-risk Localized Prostate Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Matthew Dallos</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Bristol-Myers Squibb</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Ferring Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Columbia University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to see whether immunotherapy with BMS-986218 added to degarelix&#xD;
      (which suppresses testosterone) given prior to surgery can decrease the chance that cancer&#xD;
      will come back compared to degarelix alone. People who usually have this type of prostate&#xD;
      cancer usually do not receive any additional therapy prior to surgery. Approximately 24&#xD;
      individuals will be asked to participate in this study.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a single-center, randomized, two-arm, study evaluating the safety, feasibility and&#xD;
      immunogenicity of neoadjuvant degarelix(Arm A) or BMS-986218 plus degarelix (Arm B) prior to&#xD;
      radical prostatectomy in men with high-risk localized prostate cancer (neo-RED-P). Our&#xD;
      primary objective is to characterize safety, tolerability, and feasibility of degarelix with&#xD;
      or without BMS-986218 in the neoadjuvant setting. The trial will monitor toxicity and safety,&#xD;
      as well as surgery related adverse events. The secondary objectives will be to evaluate an&#xD;
      immune response consistent with the proposed mechanism of action of BMS-986218, depletion of&#xD;
      Tregs, and to assess the pathologic complete response rate, PSA response rate and time-to-PSA&#xD;
      recurrence following treatment.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 25, 2020</start_date>
  <completion_date type="Anticipated">May 2024</completion_date>
  <primary_completion_date type="Anticipated">May 2023</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The proportion of patients with an adverse event will be reported with an exact binomial 95% confidence interval</measure>
    <time_frame>42 months</time_frame>
    <description>Characterizing the safety, tolerability, and feasibility of degarelix with or without BMS-986218 in the neoadjuvant setting. All subjects receiving at least one dose of the study drug(s) will be evaluable for toxicity.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mean Treg cell staining percentage in harvested prostate tissues will be reported and compared post-treatment between the treatment groups using paired sample test.</measure>
    <time_frame>42 months</time_frame>
    <description>The standard deviation, 95% confidence interval, median, and range of values will also be reported where appropriate</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pathological complete responses (pCR)- an absence of tumor identification on standard histological analysis of the resected prostate specimens.</measure>
    <time_frame>42 months</time_frame>
    <description>The estimate and 95% confidence intervals will be obtained.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Undetectable PSA at 12 months- the proportion of patients who achieve an undetectable PSA (&lt;0.1 ng/mL) by 12 months after prostatectomy</measure>
    <time_frame>42 months</time_frame>
    <description>The estimate and 95% confidence intervals will be obtained.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PSA response rates- a 50% change in pre-treatment and post-treatment PSA.</measure>
    <time_frame>42 months</time_frame>
    <description>These endpoints will be expressed as the proportion of men achieving a PSA response. The estimate and 95% confidence intervals will be obtained.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to PSA recurrence- the interval from the time of prostatectomy to the time when the first of at least two serial rises in PSA (≥2 weeks apart) with a PSA ≥0.2 ng/mL.</measure>
    <time_frame>42 months</time_frame>
    <description>PSA will be measured every 3 (±1) months during the first post-operative year and every 6 (±2) months during the second and third post-operative years. For subjects who have not yet demonstrated PSA relapse after 3 years followup patients will be censored at the date of the last assessment that shows a lack of PSA recurrence. This outcome will be expressed as a median (95% CI) and will be determined using the Kaplan-Meier method.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">24</enrollment>
  <condition>Prostate Cancer</condition>
  <arm_group>
    <arm_group_label>Safety lead-in</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>The first 4 subjects enrolled will be given degarelix plus BMS-986218.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm A</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Degarelix 240mg subcutaneous (SQ) x1 dose 2 weeks prior to radical prostatectomy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>BMS-986218 20mg IV every 2 weeks x 2 doses starting 3 weeks prior to radical prostatectomy plus degarelix 240mg SQ x1 dose 2 weeks prior to radical prostatectomy.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BMS-986218 and Degarelix</intervention_name>
    <description>BMS-986218 20mg IV every 2 weeks x 2 doses starting 3 weeks prior to radical prostatectomy plus degarelix 240mg subcutaneous (SQ) x1 dose 2 weeks prior to radical prostatectomy.</description>
    <arm_group_label>Arm B</arm_group_label>
    <arm_group_label>Safety lead-in</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Degarelix</intervention_name>
    <description>Degarelix 240mg SQ x1 dose 2 weeks prior to radical prostatectomy</description>
    <arm_group_label>Arm A</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Histologically confirmed adenocarcinoma of the prostate (clinical stage T1c-T3b, N0,&#xD;
             M0) without involvement of lymph nodes, bone, or visceral organs&#xD;
&#xD;
          -  Initial prostate biopsy is available for central pathologic review, and is confirmed&#xD;
             to show at least 2 positive cores and a Gleason sum of ≥4+3&#xD;
&#xD;
          -  Radical prostatectomy has been scheduled at Columbia University Irving Medical Center&#xD;
&#xD;
          -  Age ≥18 years&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group (ECOG) performance status 0-1, or Karnofsky score ≥&#xD;
             70% (see Appendix A)&#xD;
&#xD;
          -  Adequate bone marrow, hepatic, and renal function:&#xD;
&#xD;
               -  White blood cell count (WBC) &gt;3,000 cells/mm3&#xD;
&#xD;
               -  Absolute neutrophil count (ANC)&gt;1,500 cells/mm3&#xD;
&#xD;
               -  Hemoglobin &gt;9.0 g/dL&#xD;
&#xD;
               -  Platelet count &gt;100,000 cells/mm3&#xD;
&#xD;
               -  Serum creatinine &lt;1.5 × upper limit of normal (ULN)&#xD;
&#xD;
               -  Serum bilirubin &lt;1.5 × ULN&#xD;
&#xD;
               -  Alanine transaminase (ALT) &lt;3 × ULN&#xD;
&#xD;
               -  Aspartate aminotransferase (AST)&lt;3 × ULN&#xD;
&#xD;
               -  Alkaline phosphatase &lt;3 × ULN&#xD;
&#xD;
          -  Willingness to provide written informed consent and HIPAA authorization for the&#xD;
             release of personal health information, and the ability to comply with the study&#xD;
             requirements (note: HIPAA authorization will be included in the informed consent)&#xD;
&#xD;
          -  Willingness to use barrier contraception from the time of first dose of BMS-986218&#xD;
             until 165 days from the last dose of BMS-986218.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Presence of known lymph node involvement or distant metastases&#xD;
&#xD;
          -  Other histologic types of prostate cancers such as ductal, sarcomatous, lymphoma,&#xD;
             small cell, and neuroendocrine tumors&#xD;
&#xD;
          -  Prior radiation therapy, hormonal therapy, biologic therapy, or chemotherapy for&#xD;
             prostate cancer&#xD;
&#xD;
          -  Prior immunotherapy/vaccine therapy for prostate cancer&#xD;
&#xD;
          -  Concomitant treatment with other hormonal therapy or 5α-reductase inhibitors (prior&#xD;
             use of these agents is allowed).&#xD;
&#xD;
          -  Conditions requiring systemic treatment with either corticosteroids &gt; 10 mg daily&#xD;
             prednisone equivalents or other immunosuppressive medications within 14 days of study&#xD;
             treatment administration, except for adrenal replacement steroid doses &gt; 10 mg daily&#xD;
             prednisone equivalent in the absence of active autoimmune disease.&#xD;
&#xD;
             (1) Treatment with a short course of steroids (&lt; 5 days) up to 7 days prior to&#xD;
             initiating study treatment is permitted.&#xD;
&#xD;
          -  History of known or suspected autoimmune disease with the following exceptions:&#xD;
&#xD;
               -  Vitiligo&#xD;
&#xD;
               -  Resolved childhood atopic dermatitis&#xD;
&#xD;
               -  Psoriasis (with exception of psoriatic arthritis) not requiring systemic&#xD;
                  treatment (within the past 2 years).&#xD;
&#xD;
               -  Patients with Grave's disease or Hashimoto's thyroiditis that are now euthyroid&#xD;
                  clinically and by laboratory testing.&#xD;
&#xD;
          -  History of malignancy within the last 2 years, with the exception of non-melanoma skin&#xD;
             cancers and superficial bladder cancer&#xD;
&#xD;
          -  Known uncontrolled or significant cardiovascular disease including, but not limited,&#xD;
             to any of the following:&#xD;
&#xD;
               1. Myocardial infarction or stroke/transient ischemic attack within the past 6&#xD;
                  months.&#xD;
&#xD;
               2. Uncontrolled angina within the past 3 months.&#xD;
&#xD;
               3. Any history of clinically significant arrhythmias (such as ventricular&#xD;
                  tachycardia, ventricular fibrillation, or torsades de pointes).&#xD;
&#xD;
               4. History of other clinically significant heart disease (eg, cardiomyopathy,&#xD;
                  congestive heart failure with New York Heart Association functional&#xD;
                  classification III to IV, pericarditis, or significant pericardial effusion).&#xD;
&#xD;
               5. History of myocarditis, regardless of etiology.&#xD;
&#xD;
               6. Cardiovascular disease-related requirement for daily supplemental oxygen therapy.&#xD;
&#xD;
          -  Known prior or current history of HIV.&#xD;
&#xD;
          -  Patients with known untreated hepatitis B/C or those with a detectable viral load.&#xD;
&#xD;
          -  Active infection ≤7 days prior to start of treatment.&#xD;
&#xD;
          -  Live vaccine within 30 days of start of treatment.&#xD;
&#xD;
          -  Prior history of hypersensitivity to a monoclonal antibody.&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Matthew Dallos, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Assistant Professor of Medicine</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Research Nurse Navigator</last_name>
    <phone>212.342.5162</phone>
    <email>cancerclinicaltrials@cumc.columbia.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Columbia University Irving Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Research Nurse Navigator, RN</last_name>
      <phone>212-342-5162</phone>
      <email>cancerclinicaltrials@cumc.columbia.edu</email>
    </contact>
    <investigator>
      <last_name>Charles Drake, MD PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Matthew Dallos, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>March 6, 2020</study_first_submitted>
  <study_first_submitted_qc>March 6, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">March 10, 2020</study_first_posted>
  <last_update_submitted>October 27, 2021</last_update_submitted>
  <last_update_submitted_qc>October 27, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 29, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Columbia University</investigator_affiliation>
    <investigator_full_name>Matthew Dallos</investigator_full_name>
    <investigator_title>Assistant Professor of Medicine</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

